Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies

Vaccine

Volumn 21, Issue 21-22, 2003, Pages 2954-2963

  Yasuda, Yoko ^a   Isaka, Masanori ^a   Taniguchi, Tooru ^a   Zhao, Yanqiu ^a   Matano, Keiko ^a   Matsui, Hideyuki ^a   Morokuma, Kazunori ^b   Maeyama, Jun Ichi ^c   Ohkuma, Kunio ^b   Goto, Norihisa ^c   Tochikubo, Kunio ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b Chemo Sero Therapeutic Research Institute   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Anti rCTB immunity; Diphtheria toxoid; Frequent nasal immunizations; Recombinant cholera toxin B subunit (rCTB) adjuvant; Tetanus toxoid

Indexed keywords

ANTIBODY; CHOLERA TOXIN B SUBUNIT; DIPHTHERIA ANTIBODY; DIPHTHERIA VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; TETANUS ANTIBODY; TETANUS TOXOID;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BRONCHUS SECRETION; CONTROLLED STUDY; DIPHTHERIA; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NOSE SECRETION; PRIORITY JOURNAL; SALIVATION; TETANUS; VAGINA SECRETION;

EID: 12444255234     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00114-2     Document Type: Article

References (36)

1. Elson C.O., Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J. Immunol. 133(6):1984;2892-2897.
2. Elson CO. Cholera toxin as a mucosal adjuvant. In: Kiyono H, Ogra PL, McGhee JR, editors. Mucosal vaccines. Sun Diego: Academic Press; 1996. p. 59-72.
3. Ichikawa Y., Yamagata H., Tochikubo K., Udaka S. Very efficient extracellular production of cholera toxin B subunit using Bacillus brevis. FEMS Microbiol. Lett. 111(2-3):1993;219-224.
4. Yasuda Y., Matano K., Asai T., Tochikubo K. Affinity purification of recombinant cholera toxin B subunit oligomer expressed in Bacillus brevis for potential human use as a mucosal adjuvant. FEMS Immunol. Med. Microbiol. 20(4):1998;311-318.
5. Goto N., Maeyama J., Yasuda Y.et al. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Vaccine. 18(20):2000;2164-2171.
6. Tochikubo K., Isaka M., Yasuda Y.et al. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin. Vaccine. 16(2-3):1998;150-155.
7. Isaka M., Yasuda Y., Kozuka S.et al. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit. Vaccine. 16(17):1998;1620-1626.
8. Isaka M., Yasuda Y., Kozuka S.et al. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine. 18(7-8):2000;743-751.
9. Isaka M., Yasuda Y., Mizokami M.et al. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant. Vaccine. 19(11-12):2001;1460-1466.
10. Isaka M., Yasuda Y., Kozuka S.et al. Intranasal or subcutaneous co-administration of recombinant cholera toxin B subunit stimulates only a slight or no level of the specific IgE response in mice to tetanus toxoid. Vaccine. 17(7-8):1999;944-948.
11. Tochikubo K, Yasuda Y. Principles of mucosal immunity and development of mucosal vaccines using cholera toxin B subunit and its related adjuvants. In: Pandlai SG, editor. Recent Res Dev Microbiol, India, Res Signpost 2000;4:387-405.
12. Maeyama J., Isaka P.M., Yasuda Y.et al. Cytokine responses to recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Microbiol. Immunol. 45(2):2001;111-117.
13. Morokuma K. Speedy and simple determination of diphtheria and tetanus antitoxin titres by particle agglutination method. Sci. Rep. Chemo-Sero-Therap. Res. Inst. 6:1997;63-66. (in Japanese).
14. Fulthorpe A.J. Tetanus antitoxin titration by hemagglutination. J. Hyg. Camb. 55:1957;382-401.
15. Miyamura K., Nishio S., Ito A., Murata R., Kono R. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using Vero cells. I. Studies on factors affecting the toxin and antitoxin titration. J. Biol. Stand. 2:1974;189-201.
16. Thomas H.C., Parrot M.V. The induction of tolerance to a soluble protein antigen by oral administration. Immunology. 27(4):1974;631-639.
17. Tomasi T.B. Jr. Oral tolerance. Transplantation. 29(5):1980;353-356.
18. Lowrey J.A., Savage N.D.L., Palliser D.et al. Induction of tolerance via the respiratory mucosa. Int. Arch. Allergy Immunol. 116(2):1998;93-102.
19. Lycke N., Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology. 59(2):1986;301-308.
20. Tamura S.-I., Yamanaka A., Shimohara M. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine. 12(5):1994;419-426.
21. Wu H.-Y., Russell M.W. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine. 16(2-3):1998;286-292.
22. McKenzie S.J., Halsey J.F. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J. Immunol. 133(4):1984;1818-1824.
23. Bergquist C., Lagergard T., Lindblad M., Holmgren J. Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. Infect. Immun. 63(5):1995;2021-2025.
24. Sun J.-B., Holmgren J., Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. U.S.A. 91(23):1994;10795-10799.
25. Bergerot I., Ploix C., Petersen J.et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc. Natl. Acad. Sci. U.S.A. 94(9):1997;4610-4614.
26. Czerkinsky C., Holmgren J. The mucosal immune system and prospects for anti-infectious and anti-inflammatory vaccines. Immunologist. 3(3):1995;97-103.
27. Williams N.A., Hirst T.R., Nashar T.O. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. Immunol. Today. 20(2):1999;95-101.
28. Svennerholm A., Lange S., Holmgren J. Correlation between intestinal synthesis of specific immunoglobulin A and protection against experimental cholera in mice. Infect. Immun. 21(1):1978;1-6.
29. Lewis D.J.M., Castello-Branco L.R.R., Novotny P., Dougan G., Poulton T.A., Griffin G.E. Circulating cellular immune response to oral immunization of humans with cholera toxin B-subunit. Vaccine. 11(2):1993;119-121.
30. Kuziemko G.H., Stroh M., Stevens R.C. Cholera toxin binding affinity and specificity for gangliosides determined by surface plasmon resonance. Biochemistry. 35(20):1996;6375-6384.
31. George-Chandy A., Eriksson K., Lebens M., Nordstrom I., Schon E., Holmgren J. Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increased CD40 and CD86 expression on antigen-presenting cells. Infect. Immun. 69(9):2001;5716-5725.
32. Maeyama J., Isaka M., Yasuda Y.et al. Effects of recombinant cholera toxin B subunit on IL-1β production by macrophages in vitro. Microbiol. Immunol. 46(9):2002;593-599.
33. Wu H.-Y., Russell M.W. Comparison of systemic and mucosal priming for mucosal immune responses to a bacterial protein antigen given with or coupled to cholera toxin (CT) B subunit, and effects of pre-existing anti-CT immunity. Vaccine. 12(3):1994;215-222.
34. Tamura S.-I., Yajima A., Hatori E.et al. Effects of frequent intranasal administration of adjuvant-combined influenza vaccine on the protection against virus infection. Vaccine. 15(16):1997;1784-1790.
35. Tamura S.-I., Funato H., Nagamine T., Aizawa C., Kurata T. Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB. Vaccine. 7:1989;503-505.
36. Bergquist C., Lagergard T., Holmgren J. Anticarrier immunity suppresses the antibody responses to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate. Infect. Immun. 65(5):1997;1579-1583.